Impact of statins, angiotensin-converting enzyme inhibitors(ACEI), and angiotensin receptor blockers (ARBs) on reducing COPD morbidity Source: Annual Congress 2010 - COPD: management Year: 2010
Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia Source: Eur Respir J 2008; 31: 611-617 Year: 2008
Angiotensin II receptor blockers, ACE inhibitors, lung function and percent emphysema; the MESA lung study Source: Annual Congress 2012 - Asthma and COPD: quality of life and comorbidities Year: 2012
Effectiveness and safety of the antihypertensive treatment with ACE inhibitors (ACEi) and their combination with calcium antagonists (CA) of the patients with bronchial asthma (BA) and arterial hypertension (AH) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008
Clinical significance of angiotensin converting enzyme (ACE) activity in sarcoidosis Source: Eur Respir J 2001; 18: Suppl. 33, 384s Year: 2001
Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population Source: Eur Respir J 2006; 27: 1217-1222 Year: 2006
Cough among hypertensive patients treated with angiotensin convertase inhibitors. Reduction of its frequency by substitution of angiotensin convertase inhibitor with angiotensin receptor blocker. Results of non-interventional, observational postmarketing study Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011
Activity and phenotypes of angiotensin-converting enzyme (ACE) in sarcoidosis with various organ involvement Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020
Impact of blockers of AT1 receptors to angiotensin II on endothelium vasoregulating function in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 739s Year: 2006
A population-based study of statin, ARB, and ACE inhibitor use on pneumonia-related outcomes Source: Annual Congress 2011 - Severity, comorbidities and outcomes in community-acquired pneumonia Year: 2011
Effect of angiotensin II receptor antagonists on cardiovascular disorders in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 212s Year: 2001
Correlation between angiotensin-converting enzyme (ACE) gene polymorphism and exercise performance in COPD patients Source: Annual Congress 2010 - Exercise in COPD Year: 2010
Effect of angiotensin converting enzyme (ACE) gene polymorphism on diaphragmatic endurance in neonates Source: Annual Congress 2008 - Neonatal intensive care: ventilation and beyond Year: 2008
Anti-asthmatic effects of losartan, a blocker of angiotensin II type 1 receptor, in a rat model of allergic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Cardiohemodynamics changes in COPD patients while using blockers of AT1 receptors to angiotensin II Source: Eur Respir J 2006; 28: Suppl. 50, 105s Year: 2006
A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Angiotensin-converting enzyme 2 expression is not induced by the renin–angiotensin system in the lung Source: ERJ Open Res, 6 (4) 00402-2020; 10.1183/23120541.00402-2020 Year: 2020
ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS Source: Eur Respir J 2007; 29: 482-488 Year: 2007
The effect of angiotension converting enzyme inhibitors on the production of TGF-β from fibroblast Source: Eur Respir J 2006; 28: Suppl. 50, 227s Year: 2006
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004